Lypressin | CAS:50-57-7

We serve Lypressin CAS:50-57-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Lypressin

Chemical Name:Lypressin
CAS.NO:50-57-7
Synonyms:Lypressin
Lypressin Acetate
 
Physical and Chemical Properties:
Density 1.3±0.1 g/cm3
Boiling Point 1610.4±65.0 °C at 760 mmHg
Molecular Formula C46H65N13O12S2
Molecular Weight 1056.218
Flash Point 927.7±34.3 °C
Vapour Pressure 0.0±0.3 mmHg at 25°C
Index of Refraction 1.581
 
Specification:
Appearance:White to off-white powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Lysipressin Acetate is a lysine vasopressin, which retains water in the body and constricts blood vessels, It is used to treat bleeding esophageal varices.



Contact us for information like Lypressin chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Lypressin Acetate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Lypressin Acetate Use and application,Lypressin Acetate technical grade,usp/ep/jp grade.


Related News: The World Health Organisation (WHO) describes coronaviruses as a large family of viruses ranging from the common cold to more severe diseases such as Severe Acute Respiratory Syndrome (SARS), which killed nearly 800 people globally during a 2002/03 outbreak that also started in China.Benzoyl Isothiocyanate manufacturer The company’s proprietary induced pluripotent stem cell (iPSC) product platform enables mass production of off-the-shelf, engineered, homogeneous cell products that can be administered with multiple doses to deliver more effective pharmacologic activity, including in combination with cycles of other cancer treatments.1H,1H,2H,2H-Perfluorodecyltriethoxysilane supplier Patents covering oral and injectable rigosertib have been issued in the US and are expected to provide coverage until at least 2037.4,4,5,5-tetramethyl-2-(4-(triphenylen-2-yl)phenyl)-1,3,2-dioxaborolane vendor Patents covering oral and injectable rigosertib have been issued in the US and are expected to provide coverage until at least 2037.According to the business type, it can be divided into non-CMO business of APIs and intermediates and CMO business of APIs and intermediates.